Idera Pharmaceuticals, a Cambridge, Mass.-based clinical-stage biopharmaceutical company developing toll-like receptors and RNA therapeutics for patients with cancer and rare diseases, has entered into an exclusive worldwide collaboration and license agreement with GlaxoSmithKline to research, develop and commercialize selected molecules from Idera’s third-generation antisense platform for the treatment of selected targets in renal disease.
Idera is eligible to receive $100 million in development and regulatory milestone payments, including a $2.5 million upfront payment. Additionally, Idera is eligible to receive royalties on all sales upon commercialization at varying rates up to 5% on annual net sales in excess of $500 million.
“Advances in our understanding of chronic kidney disease have opened up new treatment opportunities,” said John Lepore, GSK senior vice president and head of the Metabolic Pathways and Cardiovascular Therapy Area Unit. “Idera’s antisense platform offers a new path to explore whether gene silencing technology can help stop or slow chronic kidney disease.”